CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
CD4(+) T cells control the effector function, memory, and maintenance of CD8(+) T cells. Paradoxically, we found that absence of CD4(+) T cells enhanced adoptive immunotherapy of cancer when using CD8(+) T cells directed against a persisting tumor/self-Ag. However, adoptive transfer of CD4(+)CD25(-) Th cells (Th cells) with tumor/self-reactive CD8(+) T cells and vaccination into CD4(+) T cell-deficient hosts induced autoimmunity and regression of established melanoma. Transfer of CD4(+) T cells that contained a mixture of Th and CD4(+)CD25(+) T regulatory cells (T(reg) cells) or T(reg) cells alone prevented effective adoptive immunotherapy. Maintenance of CD8(+) T cell numbers and function was dependent on Th cells that were capable of IL-2 production because therapy failed when Th cells were derived from IL-2(-/-) mice. These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective.
Antony
Paul A
PA
Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Paul.Antony@nih.gov
Piccirillo
Ciriaco A
CA
Akpinarli
Akgül
A
Finkelstein
Steven E
SE
Speiss
Paul J
PJ
Surman
Deborah R
DR
Palmer
Douglas C
DC
Chan
Chi-Chao
CC
Klebanoff
Christopher A
CA
Overwijk
Willem W
WW
Rosenberg
Steven A
SA
Restifo
Nicholas P
NP
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D049109:Cell Proliferation; D006706:Homeostasis / Q000276:immunology; D007113:Immunity, Innate; D016219:Immunotherapy, Adoptive / Q000009:adverse effects / Q000379:methods; D007376:Interleukin-2 / Q000502:physiology / Q000627:therapeutic use; D008213:Lymphocyte Activation / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D017634:Self Tolerance / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000637:transplantation*; D023001:Transplantation Tolerance / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology; D058951:gp100 Melanoma Antigen
D007376:Interleukin-2; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C548642:Pmel protein, mouse; D015375:Receptors, Interleukin-2; D058951:gp100 Melanoma Antigen
Immunity. 1999 Oct;11(4):483-93
10549630
J Immunol. 1999 Nov 15;163(10):5211-8
10553041
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7
10077623
J Exp Med. 1998 Jul 20;188(2):287-96
9670041
J Immunol. 2004 Dec 15;173(12):7259-68
15585848
J Immunol. 1999 May 1;162(9):5317-26
10228007
Eur J Immunol. 2000 Jun;30(6):1538-43
10898488
Immunity. 2000 Aug;13(2):265-76
10981969
J Immunol. 2000 Dec 1;165(11):6047-55
11086036
Trends Immunol. 2001 May;22(5):269-76
11323286
Nature. 2001 May 17;411(6835):380-4
11357146
Crit Rev Immunol. 2000;20(6):433-50
11396680
J Immunol. 2001 Aug 1;167(3):1137-40
11466326
Nat Immunol. 2001 Sep;2(9):789-92
11526387
J Exp Med. 2001 Sep 17;194(6):823-32
11560997
Ann N Y Acad Sci. 2001 Sep;941:166-76
11594570
J Immunol. 2002 Feb 1;168(3):977-80
11801627
J Immunother. 2002 May-Jun;25(3):202-6
12000861
J Immunol. 2002 Jun 15;168(12):5979-83
12055202
J Exp Med. 2002 Jun 17;195(12):1523-32
12070280
Nat Rev Immunol. 2002 Jun;2(6):389-400
12093005
J Clin Invest. 2002 Jul;110(2):185-92
12122110
Nat Immunol. 2002 Aug;3(8):756-63
12089509
Immunity. 2002 Aug;17(2):167-78
12196288
Eur J Immunol. 2002 Aug;32(8):2199-207
12209632
J Exp Med. 2002 Sep 16;196(6):851-7
12235217
J Immunol. 2002 Nov 1;169(9):4850-60
12391195
Science. 2002 Oct 25;298(5594):850-4
12242449
J Clin Invest. 2002 Nov;110(10):1415-7
12438439
Eur J Immunol. 2002 Nov;32(11):3267-75
12555672
Nature. 2003 Feb 20;421(6925):852-6
12594515
Nat Rev Immunol. 2003 Mar;3(3):253-7
12658273
Science. 2003 Apr 11;300(5617):339-42
12690202
Cancer Immun. 2002 Feb 22;2:1
12747746
J Exp Med. 2003 Jul 21;198(2):249-58
12874258
J Exp Med. 2003 Aug 18;198(4):569-80
12925674
J Exp Med. 2003 Sep 1;198(5):737-46
12939344
J Immunol. 2003 Oct 1;171(7):3435-41
14500638
J Immunol. 2003 Dec 1;171(11):5678-82
14634074
J Immunol. 2004 Feb 1;172(3):1540-7
14734732
Nat Immunol. 2004 Feb;5(2):141-9
14704792
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74
14762166
Annu Rev Immunol. 2004;22:531-62
15032588
J Immunol. 2004 Apr 1;172(7):3983-8
15034008
N Engl J Med. 2004 Apr 1;350(14):1461-3
15070799
Cell. 2004 Apr 16;117(2):265-77
15084263
J Immunol. 2004 Jun 1;172(11):6519-23
15153463
Nat Rev Immunol. 2004 Aug;4(8):595-602
15286726
Eur J Immunol. 2004 Sep;34(9):2480-8
15307180
Nat Immunol. 2004 Sep;5(9):927-33
15300249
Nat Rev Immunol. 2004 Sep;4(9):665-74
15343366
J Exp Med. 1980 Jan 1;151(1):69-80
6444236
Proc Natl Acad Sci U S A. 1985 Jun;82(12):4230-4
2987968
Science. 1993 Nov 12;262(5136):1059-61
8235625
J Virol. 1994 Dec;68(12):8056-63
7966595
J Exp Med. 1996 Aug 1;184(2):387-96
8760792
Immunol Rev. 1995 Dec;148:35-44
8825281
J Exp Med. 1997 Dec 15;186(12):2057-62
9396776
Melanoma Res. 1997 Dec;7(6):463-70
9464618
J Immunol. 1998 Feb 1;160(3):1212-8
9570536
Int Immunol. 1998 Apr;10(4):371-8
9620592